Progyny, Inc. (PGNY)

In the past six months, Progyny's stock has experienced several notable events. On November 6, 2025, Progyny announced its quarterly earnings, surpassing analysts' estimates. Analyst sentiment towards PGNY has been generally positive, with several upgrades occurring in late 2025 and early 2026. Progyny's stock has traded within a 52-week range of $17.98 to $28.75.

Demand for Progyny's products and services exhibits some seasonality, influenced by employer benefit cycles. Progyny is strategically expanding its offerings beyond core IVF and egg-freezing services to include surrogacy, donor services, adoption support, menopause care, and male-factor treatment to mitigate and smooth utilization seasonality.

Progyny, Inc. is a benefits management company specializing in fertility, family building, and women's health solutions. It offers a bundled-service model to large, self-insured U.S. employers, replacing traditional insurance plans with its Smart Cycle Benefit, which provides comprehensive coverage for fertility treatments. Progyny also offers Progyny Rx, an integrated pharmacy benefit management solution for fertility medications. The company has expanded its portfolio to include Women's Health & Family Solutions, providing holistic support beyond fertility.

Progyny's primary operations are in the United States, serving over 530 large, self-insured clients and covering approximately 6.7 million lives. Progyny acquired and rebranded Apryl as Progyny Global in September 2025, extending its services to the U.S., Europe, Latin America, and Asia.

Progyny has cultivated a strong brand reputation, recognized for its innovative approach and positive impact on patient outcomes and employer benefits. The company boasts high Net Promoter Scores (NPS) and a near 100% client retention rate. Progyny has received several accolades, including being named to the TIME100 Most Influential Companies list and recognized as a CNBC Disruptor 50.

Progyny, Inc. is predominantly owned by institutional investors, holding nearly 96% of the company's shares. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, and Fmr Llc. Company insiders hold approximately 3.14% of the shares. Individual investors and the general public hold the remaining shares.